Etanercept Therapy in Follicular Lymphoma
Etanercept Therapy in Follicular Lymphoma
批准号:
6585639
负责人:
Arnold S. Freedman
金额:
$28.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-12 至 2004-08-31
关键词:
B lymphocyte T lymphocyte chimeric proteins clinical research clinical trial phase I computed axial tomography dendritic cells drug screening /evaluation enzyme linked immunosorbent assay flow cytometry human subject human therapy evaluation immunofluorescence technique immunoglobulin G leukocyte activation /transformation neoplasm /cancer immunology neoplasm /cancer immunotherapy nonHodgkin's lymphoma patient oriented research pharmacokinetics positron emission tomography recombinant proteins rheumatoid arthritis serum tumor necrosis factor alpha
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although several novel therapeutic approaches have been developed for treatment of follicular lymphomas (FL), the overall survival has not yet been significantly improved. In vitro studies have provided evidence that FL cell survival is influenced by signals from the neoplastic microenvironment. FL cells associate with stromal elements known as follicular dendritic cells (FDCs), which provide anti-apoptotic signals to FL cells and chemotactic factors that likely contribute to the localization of FL cells within lymphoid follicles. Since FDCs provide survival and homing signals to lymphoma cells, targeting these cells in the microenvironment may be a novel treatment approach for FL. TNF( is overexpressed by FL cells, and TNF( upregulates the expression of adhesion molecules, cytokines and chemokines which are critical to FL cell-FDC interactions. Etanercept is a soluble, dimeric, recombinant human p75 TNFR, fused to the Fc fragment of human IgG1, developed for neutralization of TNF( and is an approved therapy for rheumatoid arthritis with an favorable toxicity profile. We hypothesize that TNF( blockade will affect the tumor microenvironment and therefore alter FL celI-FDC interactions, and FL cell survival. To investigate this hypothesis we propose three specific aims. First, to undertake a clinical trial of etanercept for patients with relapsed FL. Second, to investigate effects of etanercept on the tumor microenvironment directly and indirectly through studies of surrogate markers. We will investigate effects on FDCs, surrogate peripheral blood and serum markers as well as utilize PET scanning to assess the potential biologic activity of etanercept. Third, to investigate the effects of etanercept on T cell activation. Since TNF( is important in T cell function, it will be important to understand the effects of etanercept on T cells in these patients. This study is a novel approach to treating FL, where targeting the microenvironment of the tumor may inhibit the growth and survival of the neoplastic cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CpG Plus Rituximab Therapy in Follicular Lymphoma
-
批准号:6792326
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2004
-
负责人:Arnold S. Freedman
-
依托单位:
CpG Plus Rituximab Therapy in Follicular Lymphoma
-
批准号:6889316
-
项目类别:
-
资助金额:$28.27万
-
财政年份:2004
-
负责人:Arnold S. Freedman
-
依托单位:
Etanercept Therapy in Follicular Lymphoma
-
批准号:6660312
-
项目类别:
-
资助金额:$28.46万
-
财政年份:2002
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6314043
-
项目类别:
-
资助金额:$22.61万
-
财政年份:2000
-
负责人:Arnold S. Freedman
-
依托单位:
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
-
批准号:6174196
-
项目类别:
-
资助金额:$16.65万
-
财政年份:1999
-
负责人:Arnold S. Freedman
-
依托单位:
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
-
批准号:2841610
-
项目类别:
-
资助金额:$16.27万
-
财政年份:1999
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6103050
-
项目类别:
-
资助金额:$22.61万
-
财政年份:1999
-
负责人:Arnold S. Freedman
-
依托单位:
INTEGRIN SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIA
-
批准号:6377170
-
项目类别:
-
资助金额:$17.05万
-
财政年份:1999
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6269697
-
项目类别:
-
资助金额:$22.86万
-
财政年份:1998
-
负责人:Arnold S. Freedman
-
依托单位:
TRANSLATIONAL THERAPEUTIC STRATEGIES FOR LOW GRADE LYMPHOMA
-
批准号:6237543
-
项目类别:
-
资助金额:$22.11万
-
财政年份:1997
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2429747
-
项目类别:
-
资助金额:$17.75万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER ADHESION OF NORMAL/NEOPLASTIC B CELLS
-
批准号:2096409
-
项目类别:
-
资助金额:$19.09万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2096411
-
项目类别:
-
资助金额:$17.01万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2096413
-
项目类别:
-
资助金额:$17.4万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER ADHESION OF NORMAL/NEOPLASTIC B CELLS
-
批准号:3199670
-
项目类别:
-
资助金额:$18.42万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER ADHESION OF NORMAL/NEOPLASTIC B CELLS
-
批准号:3199668
-
项目类别:
-
资助金额:$17.5万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
GERMINAL CENTER INTERACTIONS OF NORMAL/MALIGNANT B CELLS
-
批准号:2712652
-
项目类别:
-
资助金额:$18.13万
-
财政年份:1991
-
负责人:Arnold S. Freedman
-
依托单位:
NCI PHYSICIAN-INVESTIGATOR DEVELOPMENT AWARD PROGRAM
-
批准号:3079608
-
项目类别:
-
资助金额:$6.33万
-
财政年份:1986
-
负责人:Arnold S. Freedman
-
依托单位:
NCI PHYSICIAN-INVESTIGATOR DEVELOPMENT AWARD PROGRAM
-
批准号:3079604
-
项目类别:
-
资助金额:$5.77万
-
财政年份:1986
-
负责人:Arnold S. Freedman
-
依托单位:
NCI PHYSICIAN-INVESTIGATOR DEVELOPMENT AWARD PROGRAM
-
批准号:3079607
-
项目类别:
-
资助金额:$6.05万
-
财政年份:1986
-
负责人:Arnold S. Freedman
-
依托单位:
海外基金